An Early Phase 1 interventional study of lateral sinus lift in Lateral Sinus Lifting, sponsored by University of Baghdad. Completed at 1 site in Iraq. Per ClinicalTrials.gov, last updated 2025-02-06.
Sponsored by University of Baghdad · Early Phase 1, Interventional, and Treatment
Background:
In sinus augmentation procedure, graft resorption remains a major dilemma of various graft materials.
Objective:
To estimate the graft volume changes following lateral sinus augmentation utilizing cone beam computed tomography.
Methods: A total of 34 lateral sinus augmentation operations were performed and 50 dental implants were concomitantly inserted. The sinus augmentation cases were distributed randomly into 3 groups according to graft material: Group A comprised utilizing deproteinized bovine bone alone, group B using deproteinized bovine bone mixed with leukocyte and platelet-rich fibrin, and group C employing deproteinized bovine bone mixed with advanced platelet-rich fibrin. Cone-beam computed tomography was obtained 2 weeks (baseline record) and 24 weeks postoperatively for the measurement of the graft volume changes.
University of Baghdad is the lead sponsor of 164 studies on the registry; 66 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Procedure: lateral sinus lift
A rectangular shaped osteotomy was performed using a low-speed surgical handpiece and round diamond bur, with copious cooled normal saline irrigation. The Schneiderian membrane (SM) was gently elevatated using Frios Sinus Set elevators for implant placement
Evaluation of graft volume changes based on CBCT imaging
Time frame: 24 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Baghdad